title: A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
abstract: The first phase of a longitudinal multicenter study comparing bromocriptine and L-dopa (as Sinemet) as de novo therapy for Parkinson's disease using a double-blind randomized design has recently been completed. Over a period of 5.5 months, bromocriptine and L-dopa were equipotent in reducing functional and neurological disability. These observations complement and extend earlier studies and suggest a role for bromocriptine as de novo therapy of Parkinson's disease.
authors.affiliation: Department of Neurology, Sunnybrook Medical Centre, Toronto, Ont., Canada.
authors.forename: R J
authors.initials: RJ
authors.lastname: Riopelle
authors.forename: M J
authors.initials: MJ
authors.lastname: Gawel
authors.forename: I
authors.initials: I
authors.lastname: Libman
authors.forename: D B
authors.initials: DB
authors.lastname: King
authors.forename: D R
authors.initials: DR
authors.lastname: McLean
authors.forename: R
authors.initials: R
authors.lastname: Paulseth
authors.forename: B
authors.initials: B
authors.lastname: Raphy
authors.forename: S
authors.initials: S
authors.lastname: Bouchard
mesh_terms: D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D011897:Random Allocation
chemical_list: D001971:Bromocriptine; D007980:Levodopa